Complete response of gallbladder cancer treated with gemcitabine and cisplatin chemotherapy combined with durvalumab:A case report and review of literature
作者机构：Department of Hepatobiliary SurgeryThe First Affiliated Hospital of Chongqing Medical UniversityChongqing 400016China
出 版 物：《World Journal of Gastrointestinal Oncology》 (世界胃肠肿瘤学杂志（英文）)
年 卷 期：2025年第17卷第1期
页 面：226-232页
学科分类：1002[医学-临床医学] 100214[医学-肿瘤学] 10[医学]
基 金：Supported by General Project of Natural Science Foundation of Chongqing,China,No.cstc2021jcyj-msxmX0604 Chongqing Doctoral"Through Train"Research Program,China,No.CSTB2022BSXM-JCX0045
主 题：Gallbladder cancer Chemotherapy Immunotherapy Durvalumab Complete response Case report
摘 要：BACKGROUND Gallbladder cancer(GBC)is the most common and aggressive subtype of biliary tract cancer(BTC)and has a poor prognosis.A newly developed regimen of gemcitabine,cisplatin,and durvalumab shows promise for the treatment of advanced ***,the efficacy of this treatment for GBC remains *** SUMMARY In this report,we present a case in which the triple-drug regimen exhibited marked effectiveness in treating locally advanced GBC,thus leading to a long-term survival benefit.A 68-year-old man was diagnosed with locally advanced GBC,which rendered him ineligible for curative *** three cycles of therapy,a partial response was *** one year of combined therapy,a clinical complete response was successfully *** maintenance therapy with durvalumab monotherapy resulted in a disease-free survival of 9 months for the *** patient experienced tolerable toxicities of reversible grade 2 nausea and *** adverse events were observed in the patient throughout the entirety of the *** The combination of gemcitabine and cisplatin chemotherapy with durvalumab was proven to be an effective treatment approach for advanced GBC,with manageable adverse *** research is warranted to substantiate the effectiveness of the combined regimen in the context of GBC.
维普期刊数据库